Books about Vasella from Amazon.com

Tells the remarkable story behind the revolutionary miracle cure for cancer, Gleevec, and describes its development by pharmaceutical company, Novartis .
Price: $1.99 [Notify me when price goes down.]

Famed for his works of physicality compounded by breathtaking size and weight, Richard Serra is one of the artists at the forefront of contemporary sculpture. He has exhibited extensively throughout the world and has created numerous permanent site-specific sculptures in public and private venues. This book accompanies Serra's sculpture project Dirk's Pod, one of the artist's major site-specific works realised in the last few years, and conceived for the Novartis Campus in Basel/Switzerland. Serra dedicated this sculpture to his friend of many years, the photographer Dirk Reinartz who died in Spring 2004. Reinartz had documented the entire production process of the sculptural elements in a series of magnificent photographs included in this book. Installation photographs and views of the finished sculpture were made by Nic Tenwiggenhorn..
Price: $19.41 [Notify me when price goes down.]

This digital document is an article from Chief Executive (U.S.), published by Thomson Gale on April 1, 2006. The length of the article is 1241 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Should CEOs take public policy stands? Novartis's Vasella thinks so. He challenged Condy Rice.(GLOBAL)(chief executive officers)(DR. DANIEL VASELLA)(Interview)
Publication:Chief Executive (U.S.) (Magazine/Journal)
Date: April 1, 2006
Publisher: Thomson Gale
Issue: 217 Page: 18(3)

Article Type: Interview

Distributed by Thomson Gale.
Price: $5.95 [Notify me when price goes down.]

This digital document is an article from Chief Executive (U.S.), published by Chief Executive Publishing on December 1, 2004. The length of the article is 1233 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Improving third world health: to display social responsibility, CEOs must respond to urgent needs.(Top Challenges Facing CEOs)
Author: Daniel Vasella
Publication:Chief Executive (U.S.) (Magazine/Journal)
Date: December 1, 2004
Publisher: Chief Executive Publishing
Issue: 204 Page: 29(2)

Distributed by Thomson Gale.
Price: $5.95 [Notify me when price goes down.]

This digital document is an article from Swiss News, published by Thomson Gale on May 1, 2007. The length of the article is 1486 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Good times over for corporate high earners? Everyone wonders if CEOs can possibly work hard enough to justify their fat paycheques. Others aren't content to wonder, and feel the Swiss people should vote on the issue. Swiss News takes a closer look at who's earning what, and talks to the businessman trying to put the brakes on astronomical salaries.(BUSINESS)
Author: Faryal Mirza
Publication:Swiss News (Magazine/Journal)
Date: May 1, 2007
Publisher: Thomson Gale
Issue: 5 Page: 10(3)

Distributed by Thomson Gale.
Price: $9.95 [Notify me when price goes down.]

This digital document is an article from Chief Executive (U.S.), published by Thomson Gale on October 1, 2007. The length of the article is 2572 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: That Vasella fella: Swiss drugmaker Novartis has brought 16 new drugs to market in the U.S. since 2000, compared to 13 for Pfizer and 9 for Merck. Now CEO Daniel Vasella is using biologics as a platform for the next stage of growth.(Company overview)
Author: J.P. Donlon
Publication:Chief Executive (U.S.) (Magazine/Journal)
Date: October 1, 2007
Publisher: Thomson Gale
Issue: 229 Page: 36(5)

Article Type: Company overview

Distributed by Thomson Gale.
Price: $9.95 [Notify me when price goes down.]

In this fictional case study by HBR Senior Editor Sarah Cliffe, a merger that looked like a marriage made in heaven to those at corporate headquarters is feeling like an infernal union to those on the ground. The merger is between Synergon Capital, a U.S. financial-services behemoth, and Beauchamp, Becker & Company, a venerable British financial-services company with strong profits and an extraordinarily loyal client base of wealthy individuals. Beauchamp also boasts a strong group of senior managers led by Julian Mansfield, a highly cultured and beloved patriarch who personifies all that's good about the company. Synergon isn't accustomed to acquiring such companies. It usually encircles a poorly managed turnaround candidate and then, once the deal is done, drops a neutron bomb on it, leaving file cabinets and contracts but no people. Before acquiring Beauchamp, Synergon's macho men offered loud assurances that they would leave the tradition-bound company alone--provided, of course, that Beauchamp met the ambitious target numbers and showed sufficient enthusiasm for cross-selling Synergon's products to its wealthy clients. In charge of making the acquisition work is Nick Cunningham, one of Synergon's more thoughtful executives. Nick, who was against the deal from the start, is the face and voice of Synergon for Julian Mansfield. And Mansfield, in his restrained way, is angry at the constant flow of bureaucratic forms, at the rude demands for instant information, at the peremptory changes. He's even dropping broad hints at retirement. Nick has already been warned: if Mansfield goes, you go..
Price: $6.50 [Notify me when price goes down.]

CEO Daniel Vasella explains why his company is placing a big bet on China's future as a world scientific power..
Price: $4.50 [Notify me when price goes down.]